IPCALABPharmaceuticals
Ipca Laboratories Ltd — PE Ratio & Valuation Analysis
₹1601.20
+1.02%
Current P/E36.41xPrice to earnings
Industry P/E31.77xSector average
4Y Avg P/E52.9x31.1% below avg
⚠️
14.6% Premium to Industry
IPCALAB P/E 36.41x vs sector avg 31.77x
📊
Historical PE Ratio
| Year | EPS (₹) | Year-end Price | PE Ratio |
|---|---|---|---|
| 2025 | ₹29.08 | ₹1419 | 48.8x |
| 2024 | ₹21.57 | ₹1695 | 78.6x |
| 2023 | ₹18.58 | ₹1113 | 59.9x |
| 2022 | ₹34.85 | ₹843 | 24.2x |
PE = Year-end closing price ÷ Diluted EPS. Source: NSE/BSE filings.
💡
Understanding Ipca Laboratories Ltd Valuation
Ipca Laboratories Ltd (IPCALAB) currently trades at 36.41x earnings. The Pharmaceuticals sector average PE is 31.77x. IPCALAB commands a premium, reflecting high growth expectations. Historically, IPCALAB has traded at an average PE of 52.9x — it is currently below that level. Always evaluate PE alongside earnings growth (PEG ratio), return on equity, debt levels and business quality. A lower PE isn't always better. Educational data only — not investment advice.
ROE
12.75%
Dividend Yield
0.28%
More on Ipca Laboratories Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.